RGDXQ (Response Genetics) Current Accrued Expense: $7.58 Mil (As of Dec. 2015)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Response Genetics Current Accrued Expense?

Response Genetics RGDXQ -99.00% Current Accrued Expense is $7.58 Mil as of Dec. 2015.

Response Genetics's Current Accrued Expense for the quarter that ended in Dec. 2015 was $7.58 Mil.

Response Genetics's quarterly Current Accrued Expense declined from Dec. 2014 ($3.76 Mil) to Mar. 2015 ($1.54 Mil) but then increased from Mar. 2015 ($1.54 Mil) to Dec. 2015 ($7.58 Mil).

Response Genetics's annual Current Accrued Expense increased from Dec. 2013 ($1.96 Mil) to Dec. 2014 ($3.76 Mil) and increased from Dec. 2014 ($3.76 Mil) to Dec. 2015 ($7.58 Mil).

Response Genetics Current Accrued Expense Related Terms

Response Genetics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Response Genetics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Response Genetics Current Accrued Expense Chart

Response Genetics Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.89 1.06 1.96 3.76 7.58

Response Genetics Quarterly Data
Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Dec15
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.95 1.78 3.76 1.54 7.58

Response Genetics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $7.58 Mil mean?
Response Genetics (RGDXQ) has a Current Accrued Expense of $7.58 Mil as of Dec. 2015. Current Accrued Expense records the total amount of accrued expenses. View historical data on Response Genetics and its competitors.
Is Response Genetics' Current Accrued Expense too high?
Response Genetics' current Current Accrued Expense is $7.58 Mil.
How does Response Genetics' Current Accrued Expense compare to PSID and GBSN?
Response Genetics' Current Accrued Expense of $7.58 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Response Genetics and its competitors. Response Genetics's current Current Accrued Expense is $7.58 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Response Genetics stock overvalued right now?
Response Genetics (RGDXQ) has a current Current Accrued Expense of $7.58 Mil. The current Current Accrued Expense is $7.58 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Response Genetics (RGDXQ), the current Current Accrued Expense is $7.58 Mil as of Dec. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Response Genetics Business Description

Address 201 Route 17 North, 2nd Floor, Rutherford, NJ, USA, 07070
Response Genetics Inc develops and sells diagnostic tests. It provides molecular- and biomarker-based tests and services which enables physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment. The group generates revenue from providing Biopharma Services, Clinical Services, and Discovery Services, of which majority of the revenue is derived from providing Biopharma Services. Biopharma services provide companies with customized solutions for patient stratification and treatment selection through molecular- and biomarker-based testing services, customized assay development and trial design consultation. The firm operates in the US and internationally and generates prime revenue from the US.